Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer

Cancer Chemotherapy and Pharmacology
Niall TebbuttDavid Goldstein

Abstract

This study assessed the safety, efficacy, and pharmacokinetics of motesanib, a multitargeted small molecule angiogenesis inhibitor, with and without panitumumab, in combination with FOLFIRI or FOLFOX in patients with metastatic colorectal cancer (mCRC). This open-label, phase 1b, two-part, multicenter study in patients with mCRC and ≤1 prior treatment evaluated escalating doses (50, 75, 100, or 125 mg QD, 75 mg BID) of motesanib with panitumumab and chemotherapy (Part 1) and the target dose of motesanib with chemotherapy (Part 2). At 17 sites in the USA and Australia, 119 patients were enrolled between December 2004 and February 2010. In Part 1 [motesanib plus panitumumab/FOLFIRI (n = 36) or plus panitumumab/FOLFOX (n = 17)], all motesanib doses tested were tolerated and 125 mg QD was deemed the target dose. Following toxicity results for combination therapy in other trials, panitumumab was withdrawn from the study. Part 2 evaluated motesanib 125 mg with chemotherapy [FOLFIRI (n = 37); FOLFOX (n = 29)]. The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-li...Continue Reading

References

May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado
Aug 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J Mayer
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzHelen X Chen
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
Jul 4, 2008·The New England Journal of Medicine·Steven I ShermanUNKNOWN Motesanib Thyroid Cancer Study Group
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Randolph HechtRafael G Amado
Feb 7, 2009·The New England Journal of Medicine·Jolien TolCornelis J A Punt
May 2, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN First BEAT investigators
Jul 1, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin J SchlumbergerSteven I Sherman
Dec 24, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George R BlumenscheinAlan Sandler
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc PeetersJennifer Gansert
Feb 16, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G R BlumenscheinUNKNOWN Motesanib NSCLC Phase II Study Investigators
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemEdward Lin
Jul 7, 2011·Clinical Colorectal Cancer·Vikram K JainDavid Cunningham
Aug 9, 2011·Clinical Colorectal Cancer·Amy S LucasRichard M Goldberg
Jun 27, 2012·AJR. American Journal of Roentgenology·Stephanie Anne Holler HowardNikhil Ramaiya
Jul 4, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giorgio V ScagliottiDavid R Spigel
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans-Joachim SchmollEric Van Cutsem
Sep 27, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollA Cervantes
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Apr 27, 2013·Expert Review of Anticancer Therapy·Timothy J PriceJeremy D Shapiro
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray

❮ Previous
Next ❯

Citations

Jan 17, 2016·BMC Medical Genetics·Natália BertoniPatricia P Reis
Mar 5, 2016·Expert Opinion on Investigational Drugs·M TampelliniG V Scagliotti
Aug 23, 2011·Clinical Colorectal Cancer·Pierre BohanesHeinz-Josef Lenz
Apr 5, 2016·Asian Pacific Journal of Cancer Prevention : APJCP·Tijen Temiz KayaGokhan Koyluoglu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.